Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Camurati-Engelmann Syndrome 1

Interventions

Temozolomide 162Radiosurgery 115Radiotherapy 100Bevacizumab 96Magnetic Resonance Spectroscopy 65Carboplatin 48Etoposide 34pembrolizumab 33Surgical Procedures, Operative 33Irinotecan 33Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 30Carmustine 28Cisplatin 25Lomustine 24Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × Trabedersen × Clear all
NCT00761280 2014-11-14

SAPPHIRE

Isarna Therapeutics GmbH

Phase 3 Terminated
27 enrolled 28 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Neoplasms

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Isarna Therapeutics GmbH

Phase 2 Completed
141 enrolled
CNS

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡